Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Abramson Cancer Center at Penn Medicine
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
* Node-negative, muscle-invasive transitional cell carcinoma of the bladder, T2-T4aN0M0 per the AJCC 4th edition staging manual.
* SWOG performance status of 0 or 1
* Adequate organ function by lab criteria (WBC \> 4,000 cells/mm3, platelets \>150,000 cells/mm3, creatinine \<1.5 md/dL (men) or \<1.3 md/dL (women), baseline liver tests \< 2 times normal limits)
* Eligible for original SWOG 8710 trial
* Had complete blood count with differential prior to first treatment (radical cystectomy or NAC).
You may not be if
* No age restrictions
* Previous or concomitant malignancy other than bladder cancer or basal cell skin cancer
* Prior pelvic radiation
* Metastatic or incurable disease
* Laboratory values exceeding those detailed in 3.1.c
* Ineligibility for the original SWOG 8710 study
* Lack of complete blood count with differential prior to first treatment (cystectomy or NAC).
Clareo Health | Neutrophil-to-Lymphocyte Ratio in Bladder Cancer: A Secondary Biomarker Analysis of SWOG 8710
